TRIM3 and breast carcinoma: Consistent with the clinical evidence, higher expression of TRIM3 in MDA-MB-134-VI, MDA-MB-175-VII, and MDA-MB-361 cells was associated with resistance to tamoxifen compared with lower expression of TRIM3 in BT-483, CAMA-1, and MCF7 (Fig. S2B, C), suggesting that TRIM3 might contribute to tamoxifen resistance in breast cancer.